搜索筛选:
搜索耗时0.6491秒,为你在为你在102,267,441篇论文里面共找到 6 篇相符的论文内容
发布年度:
[会议论文] 作者：Zhuoxuan Wu,Hongming Pan,Weidong Han,
来源：2019中国肿瘤学大会 年份：2019
...
[会议论文] 作者：Yinghua Xu,Xueli Li,Yong Dong,Xiaotong Hu,Hongming Pan,
来源：2019中国肿瘤学大会 年份：2019
Objective Colorectal cancer(CRC)is a common cancer with limited treatment options,the patients response to treatment is diverse because CRC is a biologically heterogeneous disease and arises because o...
The result of Phase 1b and phase 2 study of selective VEGFR inhibitor fruquintinib as 3+ line therap
[会议论文] 作者：Jin Li,Ruihua Xu,Junning Cao,Yuxian Bai,Jianming Xu,Tianshu Liu,Lin Shen,Liwei Wang,Hongming Pan,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Fruquintinib is a novel oral small molecule compound selectively inhibits vascular endothelial growth factor receptors (VEGFR)1, 2, and 3 with potent inhibitory effects on multiple human tu...
A multicenter, randomized, controlled trial of S-1/Cisplatin vs.Docetaxel/Cisplatin for treatment of
[会议论文] 作者：Yuankai Shi,Jianxing He,Mengzhao Wang,Baohui Han,Xiaoqing Liu,Gongyan Chen,Caicun Zhou,Jiwei Liu,Hongming Pan,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: Platinum based doublet chemotherapy is standard treatment for treatment na(i)ve advanced NSCLC pts, although molecularly targeted therapy can improve outcome of selected patients who harbor...
Efficacy and safety of regorafenib (REG) monotherapy in Chinese patients with previously treated met
[会议论文] 作者：Ruihua Xu,Jin Li,Thomas CC Yau,Brigette Ma,Hongming Pan,Jianming Xu,Yuxian Bai,Yihebali Chi,Liwei Wang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: The new oral multi-kinase inhibitor REG improves overall survival (OS) in mCRC patients who progress after standard therapies.CONCUR (NCT01584830) evaluated the efficacy and safety of REG i...
An open-label, randomized, multicenter study of S-1 vs Gemcitabine in patient with advanced pancreat
[会议论文] 作者：Bai,Jin Li,Chunmei Bai,Jifeng Feng,Minhu Chen,Dong Ma,Ying Yuan,Haijun Zhong,Shiying Yu,Min Tao,Hongming Pan,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Gemcitabine (GEM) is a standard treatment in patients with advanced pancreatic cancer (PC).S-1 has shown a good efficacy and well safety in Japanese patients from previous studies and has b...
相关搜索：
